French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Montpellier

About this trial

The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice.

Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence.

Specifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after

1. curative-intended surgery and 2. adjuvant chemotherapy.

FRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Pancreatic ductal adenocarcinoma, according to the assessment of the MDT.

Age 18 years or older.

Scheduled for curative intent surgical resection.

Disqualifiers

Hereditary pancreatic cancer.

Verified distant metastases.

Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and/or otherwise considered by the Investigator to be unlikely to complete the study.

Other cancers (excluding prior pancreatic cancer or skin cancer other than melanoma) within 3 years from eligibility screening.

Trial population

Patients with resected PDAC

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Blood sample/Liquid Biopsy

    Biological/Vaccine

    ctDNA analysis

Treatment groups

37 Participants
are divided into 1 treatment group
Group A: Pancreatic Ductal Adenocarcinoma patients1 intervention

Trial outcomes

Primary outcomes

1

3-year Disease-free survival (DFS)

Disease-free survival was defined as the time between the date of the baseline blood sampling/inclusion and the date of the first event among or recurrence or death from any cause.

Time frame
3 years after the end of inclusion

Secondary outcomes

1

Sensitivity (Se) of the ctDNA diagnostics

Sensitivity (Se) of the ctDNA diagnostics is calculated in subjects with a 3-year recurrence: Se = TP/(TP+FN) (a positive reference test)

Time frame
3 years after the end of inclusion
2

Specificity (Sp) of the ctDNA diagnostics

Specificity (Sp) of the ctDNA diagnostics is calculated in subjects without a 3-year recurrence: Sp = TN/(TN+FP) (a negative reference test)

Time frame
3 years after the end of inclusion
3

Positive predictive value of the ctDNA diagnostics

The predictive value of a positive test or positive predictive value (PPV): PPV = TP/(TP+FP).

Time frame
3 years after the end of inclusion
4

Negative predictive value of the ctDNA diagnostics

The predictive value of a negative test or negative predictive value (NPV): NPV =TN/(TN+FN).

Time frame
3 years after the end of inclusion

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.